Ward family; descendants of William Ward, who settled in Sudbury, Mass., in 1639.

Mode of access: Internet.

Petitions for damages for the diversion of Sudbury River by the city of Boston : being the petitions, testimony and arguments of counsel /

Spine title: Diversion of Sudbury River by the City of Boston.

The old house at Sudbury,

Poems.

Newton genealogy, genealogical, biographical, historical : being a record of the descendants of Richard Newton of Sudbury and Marlborough, Massachusetts 1638, with genealogies of families descended from the immigrants, Rev. Roger Newton of Milford, Connecticut, Thomas Newton of Fairfield, Connecticut, Matthew Newton of Stonington, Connecticut, Newtons of Virginia, Newtons near Boston /

Includes indexes.

History of Bethel, formerly Sudbury, Canada, Oxford County, Maine, 1768-1890;

"Family statistics": p. [457]-661.

Wills and inventories from the registers of the commissary of Bury St. Edmunds and the archdeacon of Sudbury.

Mode of access: Internet.

Reprint of a report on the origin, geological relations and composition of the nickel and copper deposits of the Sudbury Mining District, Ontario, Canada /

A revision of the original report of 1904.

A search for hep solar neutrinos at the Sudbury Neutrino Observatory

Thesis (Ph.D.)--University of Washington, 2016-08

Handmade clay balls and recycled crush glass as alternative media in water filtration

For many years materials such as quarried sand, anthracite, and granular activated carbon have been the principal media-products traditionally used in water and wastewater filtration plants. Pebble Matrix Filtration (PMF) is a novel non-chemical, sustainable pre-treatment method of protecting Slow Sand Filters (SSF) from high turbidity during heavy monsoon periods. PMF uses sand and pebbles as the filter media and the sustainability of this new technology might depend on availability and supply of pebbles and sand, both finite resources. In many countries there are two principal methods of obtaining pebbles and sand, namely dredging from rivers and beaches, and due to the scarcity of these resources in some countries the cost of pebbles is often 4-5 times higher than that of sand. In search for an alternative medium to pebbles after some preliminary laboratory tests conducted in Colombo-Sri Lanka, Poznan-Poland and Cambridge-UK, a 100-year-old brick factory near Sudbury, Suffolk, has produced hand-made clay pebbles satisfying the PMF quality requirements. As an alternative to sand, crushed recycled glass from a UK supplier was used and the PMF system was operated together with hand-made clay balls in the laboratory for high turbidity removal effectively. The results of laboratory experiments with alternative media are presented in this paper. There are potential opportunities for recycled crushed glass and clay ball manufacturing processes in some countries where they can be used as filter media.

岩浆硫化物矿床的找矿标志及找矿工作的基本方法和准则

岩浆硫化物矿床是我国Ni和铂族元素(PGE)的主要来源,同时伴有Cu、Co,经济和战略价值不言而喻,新资源基地的勘查对相关企业和整个国家长久的可持续发展都是极其重要的.加拿大Sudbury和南非Bushveld大型层状岩体中的超大型Ni-Cu-PGE和PGE硫化物矿床的大岩体成大矿的认识长期统治这这类矿床的成因研究(Naldrett,1989),直到上世纪50～60年代俄罗斯Noril'sk-Talnakh超大型Ni-Cu-PGE矿床、中国金川Ni-Cu矿床和澳大利亚西部若干与科马提岩有关的Ni-Cu-(PGE)-(Co)矿床的相继发现,才颠覆了之前认为大型岩浆硫化物矿床仅形成于大型岩体底部的观点,认识到岩浆通道系统对于这类矿床成矿的重要意义.这种矿床成因认识的飞跃对1990年代仅用了4年时间便发现并探明加拿大Voisey's Bay超大型Ni-Cu-Co矿床起到了关键性的指导作用.可见,及时吸收并运用最新理论研究成果,有助于制定正确的勘查方案,切实提高勘探工作效率,减少时间和资金浪费.本文试图根据这类矿床的成因特点,对合理设计找矿方案的基本方法和准则进行简要的论述。

Bone-targeting radiopharmaceuticals including radium-223

ABSTRACT: Bone-seeking radionuclides including samarium-153 ethylene diamine tetramethylene phosphonate and strontium-89 have been used for decades in the palliation of pain from bone metastases especially from prostate cancer. Emerging evidence of improved survival in metastatic castration-resistant prostate cancer (CRPC) with the first-in-class a-radionuclide, radium-223 (Ra) has rekindled interest in the role of bone-seeking radionuclide therapy.We review the literature for randomized controlled trials of bone-seeking radionuclides and explore some of the issues regarding the optimal use of these agents. In particular, we discuss dose, dose rate, radiobiology, and quality of radiation and postulate on potential future directions in particular combination schedules. ß-Emitting, bone-seeking radionuclides have proven ability to control pain in prostate cancer metastatic to bone with pain response rates in the order of 60% to 70% when used as single agents. Most of the published trials were underpowered to detect differences in survival; however, there is evidence of the potential for disease modification when these agents are used in combination with chemotherapy or in multiple cycles.Data from the recent phase III ALSYMPCA trial that compared Ra to placebo in symptomatic CRPC demonstrate a significant improvement in median overall survival of 3.6 months for patients with symptomatic CRPC metastatic to bone treated with 6 cycles of the a-emitting radionuclide Ra compared with placebo. The success of Ra in improving survival in CRPC will lead this agent to become part of the treatment paradigm for this disease, and with such an excellent safety profile, Ra has huge potential in combination strategies as well as for use earlier in the natural history of metastatic prostate cancer.

Molecular markers in the treatment of metastatic colorectal cancer

Although significant progress has been made in colorectal cancer (CRC) treatment within the last decade with the approval of multiple new agents, the prognosis for patients with metastatic CRC remains poor with 5-year survival rates of approximately 8%. Resistance to chemotherapy remains a major obstacle in effective CRC treatment and many patients do not receive any clinical benefit from chemotherapy. In addition, other patients will experience adverse reactions to treatment resulting in dose modifications or treatment withdrawal, which can severely reduce treatment efficacy. Currently, significant research efforts are attempting to identify reliable and validated biomarkers with which will guide clinicians to make more informed treatment decisions. Specifically, the use of molecular profiling has the potential to assist the clinician in administering the correct drug, dose, or intervention for the patient before the onset of therapy thereby selecting a treatment strategy likely to have the greatest clinical outcome while minimizing adverse events. However, until recently, personalized medicine is a paradigm that has existed more in conceptual terms than in reality with very few validated biomarkers used routinely in metastatic CRC treatment. Rapid advances in genomic, transcriptomic and proteomic technologies continues to improve our understanding of tumor biology, but the search for reliable biomarkers has turned out to be more challenging than previously anticipated with significant disparity in published literature and limited translation into routine clinical practice. Recent progress with the identification and validation of biomarkers to the anti-epidermal growth factor receptor monoclonal antibodies including KRAS and possibly BRAF provide optimism that the goal of individualized treatment is within reach. This review will highlight and discuss current progress in the search for biomarkers, the challenges this emerging field presents, and the future role of biomarkers in advancing CRC treatment.

Molecular predictors of response to antiangiogenesis therapies

Angiogenesis is a crucial component of tumor growth and metastasis. Targeting the vascular endothelial growth factor pathway represents therapeutic potentials for treating cancer. To date, 3 Food and Drug Administration-approved agents targeting angiogenesis have been developed, bevacizumab, sunitinib, and sorafenib. However, no validated biomarkers are available to identify those patients who are likely to benefit from antiangiogenesis therapy. Molecular biomarker research in antiangiogenesis inhibition is an actively growing field. Although current data are extremely promising, it is still uncertain which biomarker(s) can reliably predict their efficacy. With increasing numbers of inhibitors being developed, the need for biomarkers is more critical than ever. This review will focus on translational research that strives to identify molecular biomarkers (tissue, circulating and genomic) for approved antiangiogenesis therapies that can indicate benefit, resistance, and toxicity.

Nouvelles limites sur la détection directe de la matière sombre avec l’expérience PICASSO

Les observations astronomiques et cosmologiques suggèrent fortement la présence d’une matière exotique, non-relativiste et non-baryonique qui représenterait 26% du contenu de masse-énergie de l’Univers actuel. Cette matière dite sombre et froide serait compo- sée de particules neutres, massives et interagissant faiblement avec la matière ordinaire (WIMP : Weakly Interactive Massive Particles). Le projet PICASSO (Projet d’Identification des CAndidats Supersymétriques de la matière SOmbre) est une des expériences installées dans le site souterrain de SNOLAB à Sudbury en Ontario, qui tente de détecter directement un des candidats de la matière sombre, proposé dans le cadre des extensions supersymétriques du modèle standard : le neutralino. Pour cela, PICASSO utilise des détecteurs à gouttelettes surchauffées de C4F10, basés sur le principe de la chambre à bulles. Les transitions de phase dans les liquides surchauffés peuvent être déclenchées par le recul du 19 F, causé par une collision élastique avec les neutralinos. La nucléation de la gouttelette génère une onde sonore enregistrée par des senseurs piézo-électriques. Cette thèse présentera les récents progrès de l’expérience PICASSO qui ont conduit à une augmentation substantielle de sa sensibilité dans la recherche du neutralino. En effet, de nouvelles procédures de fabrication et de purification ont permis de réduire à un facteur de 10, la contamination majeure des détecteurs, causée par les émetteurs alpha. L’étude de cette contamination dans les détecteurs a permis de localiser la source de ces émetteurs. Les efforts effectués dans le cadre de l’analyse des données, ont permis d’améliorer l’effet de discrimination entre des évènements engendrés par les particules alpha et par les reculs nucléaires. De nouveaux outils d’analyse ont également été implémentés dans le but de discriminer les évènements générés par des particules de ceux générés par des bruits de fond électroniques ou acoustiques. De plus, un mécanisme important de suppression de bruit de fond indésirable à haute température, a permis à l’expérience PICASSO d’être maintenant sensible aux WIMPs de faibles masses.